Tier 1 — highest
Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial
The Journal of clinical endocrinology and metabolism
2020
105(4):dgz212
Bibliography
- PubMed
- PMID 31746327
- Trial registry
- View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
- Funding
- Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
- Competing interests
- A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.
Study snapshot
| Design | Prespecified safety analysis of a randomized dose-ranging trial |
|---|---|
| Model | Human participants |
| Sample | 373 adults aged 55–70 in the safety analysis |
| Intervention | Vitamin D3 400, 4,000 or 10,000 IU/day |
| Duration | 3 years |
| Endpoints | Hypercalcemia; Hypercalciuria; Renal measures; Clinical adverse events |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
Biohack Blueprint Research